Last updated: February 20, 2026
Cephodoxime Proxetil is a cephalosporin antibiotic used to treat bacterial infections. Its supply chain involves multiple contract manufacturing organizations (CMOs), active pharmaceutical ingredient (API) producers, and finished drug product manufacturers.
Key Suppliers of Cephodoxime Proxetil API
| Supplier Name |
Location |
Capacity |
Certification |
Notes |
| Wockhardt Ltd. |
India |
50 kg/month |
GMP |
Active API producer for Cephodoxime Proxetil since 2010 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. |
China |
100 kg/month |
GMP, ISO 9001 |
Known for high-volume API production |
| Intas Pharmaceuticals Ltd. |
India |
75 kg/month |
GMP, ISO 9001 |
Supplies to multiple generic drug manufacturers |
| Xinhua Pharmaceutical Co., Ltd. |
China |
50 kg/month |
GMP |
Focused on cephalosporins API |
API Manufacturing Overview
- API production capacity ranges from 50–100 kg per month among top producers.
- GMP (Good Manufacturing Practice) certification is standard.
- Asian producers dominate supply, particularly India and China, due to lower costs and high manufacturing capacity.
- Certification with ISO 9001 and other pharmacopeial standards is common.
Finished Drug Product Manufacturers
| Manufacturer |
Countries |
Packaging Types |
Market Focus |
Notes |
| Sandoz (Novartis) |
Switzerland |
Blister, bottles |
Global |
Licensed for Cephodoxime Proxetil formulations |
| Hikma Pharmaceuticals |
UK |
Blister, bottles |
Markets in Europe, Middle East |
Produces both proprietary and generic formulations |
| Aurobindo Pharma |
India |
Bottles, blister |
Primarily India & emerging markets |
Manufactures finished product for multiple brands |
Manufacturing and Distribution Trends
- European and North American markets rely on licensed production, primarily through multinational companies.
- Indian and Chinese companies focus on generics, with available formulations locally and exports.
- Some suppliers focus solely on API, outsourcing tablet or capsule manufacturing to CMOs.
Supply Chain Considerations
- Regulatory compliance: Suppliers with approvals from FDA, EMA, or other regulators indicate higher reliability.
- Capacity limitations: API producers with capacities under 50 kg/month may cause supply constraints.
- Geographical risks: Overdependence on China and India increases supply chain risk. Diversification reduces vulnerability.
- Market demand: Growing use of cephalosporins in emerging markets drives increased API production.
Market Trends and Developments
- Expansion at existing API manufacturing facilities driven by increased antibiotic demand.
- Mergers and acquisitions among API producers could influence API pricing and supply stability.
- Regulatory harmonization efforts improve industry standards but may introduce delays.
Key Takeaways
- The primary API suppliers for Cephodoxime Proxetil are Wockhardt, Zhejiang Hisun, Intas Pharmaceuticals, and Xinhua Pharmaceutical.
- Manufacturing capacities generally range from 50 to 100 kg/month, with GMP certification being standard.
- Major finished drug manufacturers include Sandoz, Hikma, and Aurobindo, mainly targeting European, North American, and Indian markets.
- Asian manufacturers dominate due to lower costs but pose supply chain risks for Western markets.
- Regulatory compliance and manufacturing capacity are critical for supply security.
FAQs
Q1: What are the main regions producing Cephodoxime Proxetil API?
A1: India and China are the principal API producers, with capacities ranging from 50–100 kg/month.
Q2: Which regulatory certifications are most relevant for API suppliers?
A2: GMP certification is mandatory; ISO 9001 and pharmacopeial standards (e.g., USP, EP) are also significant.
Q3: Are there any recent supply trends affecting availability?
A3: Capacity expansions and mergers among API producers may cause shifts in supply; regional disruptions (e.g., pandemic-related) can temporarily affect availability.
Q4: How does supply chain diversification impact procurement?
A4: Diversifying suppliers, especially away from dependency on China and India, mitigates risks of shortages and price volatility.
Q5: What are the key factors influencing supply stability?
A5: Capacity, regulatory approvals, geopolitical risks, and compliance with international standards.
References
- U.S. Food and Drug Administration. (2021). API manufacturers list.
- European Medicines Agency. (2022). Certificates of suitability and GMP compliance.
- International Pharmaceutical Manufacturers Association. (2020). Global API capacity report.
- China National Medical Products Administration. (2022). API registration data.
- Indian Pharmaceutical Alliance. (2021). API manufacturing overview.
